Filing Overview
Xilio Therapeutics, Inc. filed a Form 8-K dated December 19, 2022, with the report signed on December 23, 2022. The filing reports an executive departure under Item 5.02. Xilio is a clinical-stage biotechnology company; this filing does not provide operating or financial results.
Material Event
- Edward C. English notified the company on December 19, 2022, of his resignation as vice president, finance, accounting and treasury and principal accounting officer.
- His resignation is effective January 31, 2023.
- The stated reason is to pursue other opportunities.
Financial and Operating Information
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, cash runway, guidance, or other financial metrics. It also does not disclose severance, replacement arrangements, or other compensation terms related to the resignation.
Outlook, Risks and Unusual Items
The departure of the principal accounting officer may create a finance and reporting transition risk, but the filing does not describe any operational disruption, internal-control issue, accounting disagreement, contingency, or successor appointment. No management outlook or guidance is included.
Key Facts to Verify
- Whether Xilio appointed a successor or interim principal accounting officer after January 31, 2023.
- Whether subsequent filings disclose transition costs, severance, or changes in finance leadership.
- Whether subsequent periodic reports identify any internal-control, financial-reporting, or audit-related effects.